Aarti Drugs · NSE: AARTIDRUGS · BSE: 524348
Q2 FY25 results · Jul–Sep 2024
Aarti Drugs reported revenue from operations of ₹598.33 crore (down 6.7% from Q2 FY24) and net profit of ₹34.96 crore (down 11.7% from Q2 FY24) for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 598.33 | 641.54 | −6.7% | 555.34 | +7.7% |
| Other income | 1.48 | 0.68 | +117.6% | 1.11 | +33.3% |
| Total income | 599.81 | 642.22 | −6.6% | 556.45 | +7.8% |
| Profit before tax | 45.88 | 56.27 | −18.5% | 43.98 | +4.3% |
| Net profit for the period | 34.96 | 39.60 | −11.7% | 33.27 | +5.1% |
| Attributable to shareholders of the company | 35.01 | 39.59 | −11.6% | 33.24 | +5.3% |
| EPS, basic (₹) | 3.83 | 4.29 | −10.7% | 3.62 | +5.8% |
| Net margin (%) | 5.8 | 6.2 | 6.0 |
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 543.09 | 577.54 | −6.0% | 492.96 | +10.2% |
| Other income | 0.38 | 0.74 | −48.6% | 0.11 | +245.5% |
| Total income | 543.47 | 578.28 | −6.0% | 493.07 | +10.2% |
| Profit before tax | 40.89 | 46.83 | −12.7% | 35.16 | +16.3% |
| Net profit for the period | 30.39 | 34.58 | −12.1% | 26.91 | +12.9% |
| EPS, basic (₹) | 3.33 | 3.75 | −11.2% | 2.93 | +13.7% |
| Net margin (%) | 5.6 | 6.0 | 5.5 |
Consolidated
- Filed with BSE
- 25 Oct 2024, 15:29 IST
- Board meeting
- 24 Oct 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 25 Oct 2024, 15:29 IST
- Board meeting
- 24 Oct 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Audited
- Source
- XBRL filing on BSE